Director Richard Maroun receives 38,040 stock options at Whitehawk (WHWK)

Rhea-AI Filing Summary

Whitehawk Therapeutics director Richard E. Maroun received a grant of stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036. All 38,040 option shares will vest in a single tranche, subject to his continued service, on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting following that date. After this award, he holds 38,040 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Maroun Richard E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,040	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 38,040 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 38,040 shares Exercise price: $4.16 per share Expiration date: June 12, 2036 +1 more

4 metrics

Options granted 38,040 shares Stock option grant to director Richard E. Maroun

Exercise price $4.16 per share Strike price for the 38,040 stock options

Expiration date June 12, 2036 Option term end for the granted stock options

Post-transaction derivative holdings 38,040 derivative securities Total stock options held directly after the grant

Key Terms

Stock Option, Equity Incentive Plan, Service Provider, Date of Grant

4 terms

Stock Option financial

"Stock Option (right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Equity Incentive Plan financial

"defined in the Issuer's 2021 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

Date of Grant financial

""Date of Grant" shall mean June 12, 2026."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maroun Richard E

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.16	06/12/2026		A		38,040		(1)	06/12/2036	Common Stock	38,040	$0	38,040	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Whitehawk Therapeutics (WHWK) report in this Form 4?

Whitehawk Therapeutics reported that director Richard E. Maroun received a grant of stock options for 38,040 shares. These options give him the right to buy common stock at a fixed price if service-based vesting conditions are met.

How many Whitehawk Therapeutics (WHWK) options were granted to Richard Maroun?

Richard Maroun was granted stock options covering 38,040 shares of Whitehawk Therapeutics common stock. This full amount represents his derivative holdings following the transaction, as reported in the Form 4 insider filing.

What is the exercise price of the Whitehawk Therapeutics (WHWK) options?

The stock options granted to Richard Maroun have an exercise price of $4.16 per share. This means he can purchase Whitehawk Therapeutics common stock at $4.16 once the options vest and are otherwise exercisable.

When do Richard Maroun’s Whitehawk (WHWK) stock options vest?

All 38,040 option shares vest together, subject to continued service, on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting following that date.

Are the Whitehawk Therapeutics (WHWK) options granted to Richard Maroun currently in the money?

The Form 4 states an exercise price of $4.16 per share but does not provide any market price information. It only confirms the grant terms and vesting conditions for the 38,040 stock options awarded.